drug development
The End of an Era: Why Phasing Out Animal Testing is Biotech’s Next Multi-Trillion Dollar Investment Opportunity
A major regulatory shift is ending the era of mandated animal testing, creating a massive financial and competitive advantage for biotech firms.
The $9.4 Billion Bet on Code: Why Thermo Fisher’s Mega-Deal for a Software Company Is Reshaping Medicine
Thermo Fisher’s $9.4B acquisition of Clario isn’t just a deal; it’s a bet on the future of medicine, powered by software, AI, and cloud technology.
Thermo Fisher’s $10 Billion Bet: Unpacking the Mega-Deal for Clario and the Future of Drug Development
Thermo Fisher’s potential $10B acquisition of Clario signals a major shift in the drug development landscape, blending healthcare, data, and finance.
The $600M Bet: How the Global Race for Weight-Loss Drugs is Rewriting the Rules of Biotech Investing and Tapping into China’s R&D Power
A US biotech’s $600M raise for weight-loss drugs reveals a key strategy: using China for faster, cheaper clinical trials, altering biotech investing.